Is IXHL or TTRX more profitable?

Turn Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% Turn Therapeutics N/A N/A N/A

Is EQ or IXHL more profitable?

Equillium's return on equity of -61.43% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -61.43% -53.72% Incannex Healthcare N/A -81.01% -76.11%

Incannex Healthcare (IXHL) Competitors

$3.31 +0.06 (+1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$3.33 +0.02 (+0.60%)

As of 07:29 PM Eastern

Compare

IXHL vs. MDWD, IMDX, TNXP, TTRX, and EQ

Should you buy Incannex Healthcare stock or one of its competitors? MarketBeat compares Incannex Healthcare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Incannex Healthcare include MediWound (MDWD), Oncocyte (IMDX), Tonix Pharmaceuticals (TNXP), Turn Therapeutics (TTRX), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry.

How does Incannex Healthcare compare to MediWound?

MediWound (NASDAQ:MDWD) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

MediWound has higher revenue and earnings than Incannex Healthcare. MediWound is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.66	-$23.88M	-$2.26	N/A
Incannex Healthcare	$90K	440.23	-$46.88M	-$1.55	N/A

Incannex Healthcare has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
Incannex Healthcare	N/A	-81.01%	-76.11%

46.8% of MediWound shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MediWound has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7, indicating that its stock price is 600% more volatile than the broader market.

In the previous week, MediWound's average media sentiment score of 0.00 equaled Incannex Healthcare'saverage media sentiment score.

Company	Overall Sentiment
MediWound	Neutral
Incannex Healthcare	Neutral

MediWound presently has a consensus price target of $34.00, indicating a potential upside of 141.65%. Incannex Healthcare has a consensus price target of $18.00, indicating a potential upside of 443.81%. Given Incannex Healthcare's higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

MediWound beats Incannex Healthcare on 8 of the 14 factors compared between the two stocks.

How does Incannex Healthcare compare to Oncocyte?

Incannex Healthcare (NASDAQ:IXHL) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Incannex Healthcare has higher earnings, but lower revenue than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	440.23	-$46.88M	-$1.55	N/A
Oncocyte	$4.05M	42.81	-$50.22M	-$1.48	N/A

Incannex Healthcare has a beta of 7, indicating that its share price is 600% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

Incannex Healthcare has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Oncocyte	-2,454.64%	N/A	-96.96%

In the previous week, Oncocyte had 1 more articles in the media than Incannex Healthcare. MarketBeat recorded 1 mentions for Oncocyte and 0 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score.

Company	Overall Sentiment
Incannex Healthcare	Neutral
Oncocyte	Neutral

Incannex Healthcare currently has a consensus target price of $18.00, indicating a potential upside of 443.81%. Oncocyte has a consensus target price of $12.00, indicating a potential upside of 123.46%. Given Incannex Healthcare's higher possible upside, equities research analysts clearly believe Incannex Healthcare is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 55.4% of Oncocyte shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 2.2% of Oncocyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Incannex Healthcare beats Oncocyte on 7 of the 13 factors compared between the two stocks.

How does Incannex Healthcare compare to Tonix Pharmaceuticals?

Incannex Healthcare (NASDAQ:IXHL) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Incannex Healthcare has a beta of 7, indicating that its share price is 600% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

Incannex Healthcare presently has a consensus target price of $18.00, indicating a potential upside of 443.81%. Tonix Pharmaceuticals has a consensus target price of $22.00, indicating a potential upside of 83.95%. Given Incannex Healthcare's higher probable upside, analysts clearly believe Incannex Healthcare is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Incannex Healthcare has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

In the previous week, Tonix Pharmaceuticals' average media sentiment score of 1.44 beat Incannex Healthcare's score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Incannex Healthcare	Neutral
Tonix Pharmaceuticals	Positive

Incannex Healthcare has higher earnings, but lower revenue than Tonix Pharmaceuticals. Incannex Healthcare is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	440.23	-$46.88M	-$1.55	N/A
Tonix Pharmaceuticals	$13.11M	14.54	-$124.02M	-$14.36	N/A

Summary

Tonix Pharmaceuticals beats Incannex Healthcare on 9 of the 16 factors compared between the two stocks.

How does Incannex Healthcare compare to Turn Therapeutics?

Incannex Healthcare (NASDAQ:IXHL) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Turn Therapeutics has lower revenue, but higher earnings than Incannex Healthcare. Turn Therapeutics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	440.23	-$46.88M	-$1.55	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

In the previous week, Turn Therapeutics had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 2 mentions for Turn Therapeutics and 0 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.00 beat Turn Therapeutics' score of -0.36 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Neutral
Turn Therapeutics	Neutral

Turn Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Turn Therapeutics	N/A	N/A	N/A

0.4% of Incannex Healthcare shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Incannex Healthcare presently has a consensus price target of $18.00, suggesting a potential upside of 443.81%. Turn Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 33.56%. Given Incannex Healthcare's higher probable upside, equities analysts plainly believe Incannex Healthcare is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Incannex Healthcare beats Turn Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Incannex Healthcare compare to Equillium?

Equillium (NASDAQ:EQ) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, Equillium had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 2 mentions for Equillium and 0 mentions for Incannex Healthcare. Equillium's average media sentiment score of 0.00 equaled Incannex Healthcare'saverage media sentiment score.

Company	Overall Sentiment
Equillium	Neutral
Incannex Healthcare	Neutral

Equillium has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7, indicating that its stock price is 600% more volatile than the broader market.

Equillium's return on equity of -61.43% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
Incannex Healthcare	N/A	-81.01%	-76.11%

Equillium presently has a consensus target price of $7.57, indicating a potential upside of 166.60%. Incannex Healthcare has a consensus target price of $18.00, indicating a potential upside of 443.81%. Given Incannex Healthcare's higher probable upside, analysts clearly believe Incannex Healthcare is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

27.1% of Equillium shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Equillium has higher revenue and earnings than Incannex Healthcare. Equillium is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	4.37	-$22.40M	-$0.32	N/A
Incannex Healthcare	$90K	440.23	-$46.88M	-$1.55	N/A

Summary

Equillium beats Incannex Healthcare on 11 of the 15 factors compared between the two stocks.

Get Incannex Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXHL vs. The Competition

Export

Metric	Incannex Healthcare	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$38.88M	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-2.14	18.43	24.92	23.97
Price / Sales	440.23	336.82	528.81	109.59
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	1.60	4.11	10.79	6.50
Net Income	-$46.88M	$64.45M	$3.56B	$336.88M
7 Day Performance	-11.26%	2.24%	1.67%	-0.22%
1 Month Performance	-5.97%	1.04%	0.43%	0.77%
1 Year Performance	-44.83%	30.05%	32.84%	31.57%

Incannex Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXHL Incannex Healthcare	1.4578 of 5 stars	$3.31 +1.8%	$18.00 +443.8%	-50.6%	$38.88M	$90K	N/A	3	Gap Down
MDWD MediWound	2.5821 of 5 stars	$13.95 -1.9%	$34.00 +143.7%	-26.9%	$182.76M	$16.96M	N/A	80
IMDX Oncocyte	1.9263 of 5 stars	$5.70 +1.6%	$12.00 +110.5%	N/A	$181.15M	$4.05M	N/A	120	News Coverage Gap Up
TNXP Tonix Pharmaceuticals	3.9515 of 5 stars	$11.52 +1.5%	$22.00 +91.0%	-62.3%	$180.93M	$13.11M	N/A	50	Positive News Gap Down
TTRX Turn Therapeutics	2.2143 of 5 stars	$6.42 +6.1%	$8.00 +24.6%	N/A	$180.07M	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IXHL) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incannex Healthcare (IXHL) Competitors

IXHL vs. MDWD, IMDX, TNXP, TTRX, and EQ

How does Incannex Healthcare compare to MediWound?

Summary

How does Incannex Healthcare compare to Oncocyte?

Summary

How does Incannex Healthcare compare to Tonix Pharmaceuticals?

Summary

How does Incannex Healthcare compare to Turn Therapeutics?

Summary

How does Incannex Healthcare compare to Equillium?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Incannex Healthcare (IXHL) Competitors

IXHL vs. MDWD, IMDX, TNXP, TTRX, and EQ

How does Incannex Healthcare compare to MediWound?

Which has stronger earnings and valuation, MDWD or IXHL?

Is MDWD or IXHL more profitable?

Do insiders & institutionals believe in MDWD or IXHL?

Which has more volatility and risk, MDWD or IXHL?

Does the media favor MDWD or IXHL?

Do analysts recommend MDWD or IXHL?

Summary

How does Incannex Healthcare compare to Oncocyte?

Which has higher valuation and earnings, IXHL or IMDX?

Which has more risk & volatility, IXHL or IMDX?

Is IXHL or IMDX more profitable?

Does the media favor IXHL or IMDX?

Do analysts prefer IXHL or IMDX?

Do institutionals and insiders believe in IXHL or IMDX?

Summary

How does Incannex Healthcare compare to Tonix Pharmaceuticals?

Do insiders & institutionals believe in IXHL or TNXP?

Which has more volatility & risk, IXHL or TNXP?

Do analysts rate IXHL or TNXP?

Is IXHL or TNXP more profitable?

Does the media refer more to IXHL or TNXP?

Which has better valuation and earnings, IXHL or TNXP?

Summary

How does Incannex Healthcare compare to Turn Therapeutics?

Which has stronger valuation & earnings, IXHL or TTRX?

Does the media prefer IXHL or TTRX?

Is IXHL or TTRX more profitable?

Do insiders and institutionals hold more shares of IXHL or TTRX?

Do analysts recommend IXHL or TTRX?

Summary

How does Incannex Healthcare compare to Equillium?

Does the media refer more to EQ or IXHL?

Which has more risk & volatility, EQ or IXHL?

Is EQ or IXHL more profitable?

Do analysts rate EQ or IXHL?

Do institutionals & insiders believe in EQ or IXHL?

Which has stronger valuation and earnings, EQ or IXHL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools